Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The p53/MDM2/MDMX-targeted therapies—a clinical synopsis

17 Apr 2020

Abstract excerpt

The cost of cancer care accelerates because of the growing number of cancer patients and the increasing expenses of drug innovations. The approval of costly second-line therapies like immune checkpoint inhibitors or CAR-T therapies contributes to this trend. Hence, drug repurposing, which uses drugs originally approved for other indications, is emerging as a necessary approach in cancer care, due to its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cancer Research and Treatments
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32303678
DOI: 10.1038/s41419-020-2445-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The p53/MDM2/MDMX-targeted therapies—a clinical synopsisPMID 32303678Read ↗

A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)Semantic proximity Read ↗

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trialsSemantic proximity Read ↗

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)Semantic proximity Read ↗

MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)Semantic proximity Read ↗

p53–Mdm2 inhibitors: patent review (2009 – 2010)Semantic proximity Read ↗

MDM2 Antagonists and p53-Targeting Therapies in Cancer: Clinical Applications, Adverse Effects, and Resistance MechanismsSemantic proximity Read ↗

Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell DeathSemantic proximity Read ↗

Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer TherapySemantic proximity Read ↗

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?Semantic proximity Read ↗

Clinical Overview of MDM2/X-Targeted TherapiesSemantic proximity Read ↗

Targeting MDMX for Cancer Therapy: Rationale, Strategies, and ChallengesSemantic proximity Read ↗

Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) AntagonistsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.